Trials / Completed
CompletedNCT03052478
Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression
Phase II, Single-arm Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
There is no accepted standard therapy for patients with advanced gastric cancer who have progressed during or after second-line therapy. The role of 3rd line treatment in advanced gastric cancer has not been proven. As a novel target of gastric cancer, SMO overexpression is chosen in this study, and the investigators plan this study to evaluate the efficacy and safety of vismodegib in gastric cancer. The doses of vismodegib are based on trials of basal cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vismodegib 150 mg | Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle. |
Timeline
- Start date
- 2017-02-10
- Primary completion
- 2019-12-31
- Completion
- 2020-09-10
- First posted
- 2017-02-14
- Last updated
- 2021-06-08
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03052478. Inclusion in this directory is not an endorsement.